Osicent (Osimertinib) 80mg*30 | Incepta Bangladesh Generic | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

Generic Information: Osicent (Osimertinib) 80mg — Bangladesh

Osicent is the osimertinib generic made by Incepta Pharmaceuticals Ltd., the largest pharmaceutical manufacturer in Bangladesh by volume. Supplied as 80 mg film-coated tablets in a 30-tablet pack, Osicent matches the originator's standard strength and is one of the recognised Bangladeshi osimertinib brands alongside Everest's Osimert and Beacon's Tagrix. Incepta's scale and export reach mean Osicent is widely available across South Asia and in export markets.

For buyers, Osicent represents a cost-effective generic whose manufacturer is well established, which can simplify verification and ongoing supply. The active ingredient and dose are identical to the originator Tagrisso.

What Is Osicent Used For?

Osicent treats EGFR mutation-positive non-small cell lung cancer across first-line, adjuvant and T790M-positive settings. It is used first-line for advanced disease with EGFR sensitising mutations, after surgery in eligible early-stage patients, and after resistance to a first- or second-generation EGFR TKI when the T790M mutation is present. Its CNS activity supports use in brain-metastatic disease.

How Does Osicent Work?

Osimertinib, the active ingredient in Osicent, is an irreversible mutant-selective EGFR inhibitor. It covalently binds EGFR bearing exon 19 deletions, L858R mutations and T790M, blocking tumour-growth signalling while sparing wild-type EGFR. This mechanism accounts for both its broad efficacy and its generally milder rash and diarrhoea.

Indications

  • First-line advanced EGFR-mutant NSCLC.
  • Adjuvant treatment after resection of EGFR-mutant NSCLC.
  • T790M-positive NSCLC after prior EGFR-TKI therapy.

Dosage and Administration

The dose is 80 mg once daily, with or without food, swallowed whole. A missed dose beyond 12 hours is skipped. The dose may be reduced to 40 mg daily to manage side effects, and therapy continues until disease progression or unacceptable toxicity.

Side Effects

Common side effects are diarrhoea, rash, dry skin, nail changes, stomatitis and fatigue. Interstitial lung disease, QT prolongation and cardiomyopathy are rare but serious; patients should report new respiratory symptoms or palpitations and receive routine cardiac and liver monitoring.

Storage

Store Osicent below 30°C, in the original package, in a dry place, out of children's reach. Do not use after the expiry date.

Why Choose the GLT?

GLT sources Osicent through verified Bangladeshi channels and confirms manufacturer and batch details before shipping. Bangladeshi generics like Osicent are typically priced several times lower than branded osimertinib in Western markets, making sustained targeted therapy more affordable for patients and institutions. We offer clear documentation and responsive support through ordering and delivery.

How to Order Osicent from GLT

Contact GLT on WhatsApp at +86 15234153837 or email [email protected] to order Osicent 80 mg (30 tablets). Provide your quantity, destination and order type, and we will confirm availability, batch documentation and shipping terms.

FAQ

Who manufactures Osicent? Osicent is manufactured by Incepta Pharmaceuticals Ltd., the largest pharmaceutical company in Bangladesh.

Is Osicent a generic of Tagrisso? Yes, Osicent contains the same active ingredient (osimertinib) at the same 80 mg dose.

Can I order Osicent online? Yes, GLT can supply Osicent internationally; contact us via WhatsApp or email.

Related Oncology Products

Tirzema (Tirzepatide) 2.5/5/7.5mg/0.5mL Single-Dose Pen | Incepta Bangladesh | GLT

Tirzema — Incepta Pharmaceuticals tirzepatide single-dose pen, three official strengths (2.5/5/7.5mg/0.5mL) for T2DM and weight...

Orforglipron (LuciOrfor) 0.8–17.2mg Tablets | Laos Generic Oral GLP-1 | GLT

Lucius Pharmaceuticals (Laos) generic orforglipron, 6-dose titration for weight management

Orforglipron (OriYo) 0.8–17.2mg Tablets | Bangladesh Generic Oral GLP-1 | GLT

National Drug Co. generic orforglipron, 6-dose titration for weight management

Olumiant (Baricitinib) 2mg/4mg Tablets | JAK1/JAK2 Inhibitor | Eli Lilly USA | GLT

Eli Lilly's selective JAK1/JAK2 inhibitor for rheumatoid arthritis, atopic dermatitis and severe alopecia areata.

Barinat (Baricitinib) 4mg | Generic JAK1/JAK2 Inhibitor | Natco Pharma Limited | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Natco Pharma Limited (India) — an affordable alternative to Olumiant...

AVATODX (Avatrombopag) 20mg*30 Tablets | Bigbear Pharmaceutical Laos | GLT

AVATODX — avatrombopag 20mg by Bigbear Pharmaceutical (Lao) Co., Ltd., Lao Reg. 06L0985/23, 30-tablet bottle

KeZeRui 科瑞泽 (Avatrombopag) 20mg*10 Tablets | Sichuan Kelun China | GLT

KeZeRui — national-procurement avatrombopag from Sichuan Kelun Pharmaceutical, China's integrated API + tablet maker

Tixepa (Tirzepatide) 20mg/2mL & 30mg/2mL Multi-Dose Pen | Drug International | GLT

Tixepa — Drug International Limited (DIL) tirzepatide multi-dose pen, two official strengths (Tixepa-5 = 20mg/2mL,...